Willis Johnson & Associates Inc. Reduces Stock Position in Eli Lilly and Company (NYSE:LLY)

Willis Johnson & Associates Inc. trimmed its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 48.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 370 shares of the company's stock after selling 342 shares during the quarter. Willis Johnson & Associates Inc.'s holdings in Eli Lilly and Company were worth $286,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Grassi Investment Management raised its holdings in shares of Eli Lilly and Company by 0.3% during the fourth quarter. Grassi Investment Management now owns 79,512 shares of the company's stock worth $61,383,000 after purchasing an additional 225 shares during the last quarter. Elevate Capital Advisors LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $262,000. Capital & Planning LLC raised its stake in shares of Eli Lilly and Company by 15.6% during the 4th quarter. Capital & Planning LLC now owns 481 shares of the company's stock valued at $371,000 after buying an additional 65 shares during the last quarter. Integrated Investment Consultants LLC lifted its holdings in shares of Eli Lilly and Company by 0.3% in the 4th quarter. Integrated Investment Consultants LLC now owns 696,167 shares of the company's stock valued at $537,441,000 after buying an additional 2,000 shares during the period. Finally, Howard Financial Services LTD. boosted its stake in shares of Eli Lilly and Company by 47.0% in the fourth quarter. Howard Financial Services LTD. now owns 632 shares of the company's stock worth $488,000 after buying an additional 202 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 0.3%

Shares of LLY opened at $754.95 on Tuesday. The stock has a 50 day moving average price of $796.49 and a 200 day moving average price of $805.24. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market capitalization of $715.49 billion, a price-to-earnings ratio of 64.47, a PEG ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the prior year, the business posted $2.58 earnings per share. The business's quarterly revenue was up 45.2% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

LLY has been the subject of several recent research reports. Cantor Fitzgerald began coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target for the company. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Finally, Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.